Study on the Value of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET) Information in Subtype of Metastatic Breast Cancer
A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET)InformatiOn IN Subtype of Metastatic Breast Cancer(MBC)
Study Type
OBSERVATIONAL
Enrollment
50
biopsy or surgical pathology in extrahepatic/liver/brain metastases
68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Shanghai Cancer Center Institutional Review Board
Shanghai, Shanghai Municipality, China
RECRUITINGVerify the subtype value of dual-PET in extrahepatic metastases
Verify whether the subtype value of FES-PET and HER2-PET is consistent with biopsy or surgical pathology in extrahepatic metastases.
Time frame: 2 year
Verify the HER2-PET value in liver metastasis
Verify whether the HER2-PET value is consistent with biopsy or surgical pathology in liver metastasis.
Time frame: 2 year
Verify the HER2-PET value in brain metastasis
Verify whether the HER2-PET value is consistent with biopsy or surgical pathology in brian metastasis.
Time frame: 2 year
Heterogeneity in metastatic lesions
Observe the heterogeneity of ER and HER2 expression in metastatic lesions.
Time frame: 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.